Introduction

Knee pain from joint wear is common and can affect people of all ages. Physiotherapy, anti-inflammatory medication, and joint injections are mainstays of conservative care, but they do not always provide lasting relief. For patients who want a biologically active, non-surgical option before considering an operation, the ChondroFiller injection is one approach worth understanding clearly.

This article explains what ChondroFiller is, how the injection works in a clinical setting, who it may suit, and what realistic expectations look like — alongside a brief note on when a surgical pathway is more appropriate.

Understanding Knee Joint Wear

Articular cartilage lines the ends of the bones in the knee and allows the joint to move freely under load. Unlike most tissues, it has a very limited capacity to repair itself once damaged. Wear from injury, overuse, or osteoarthritis can cause the surface to thin and fray, leading to pain, swelling, stiffness, and reduced function.

Treatment choices span a broad range — from physiotherapy and weight management to injectable therapies and, where necessary, surgical reconstruction. The right choice depends on the size and depth of the defect, the patient's age and activity level, and their overall joint health. No single option suits everyone, and cartilage wear is not reversible in the conventional sense.

What Is ChondroFiller?

ChondroFiller is a Class III CE-marked medical device made by Meidrix Biomedicals, Germany. It is an acellular (cell-free) collagen scaffold composed primarily of Type I collagen. When delivered into a cartilage defect, the two-component system self-gels within approximately three to five minutes, filling the space and forming a biocompatible matrix.

The scaffold is designed to recruit the patient's own progenitor cells from the surrounding tissue and subchondral bone into the defect site. These cells can then populate the matrix, differentiate, and begin to lay down new cartilage-like tissue. The process is described as acellular matrix-induced chondrogenesis — the scaffold provides the structure; the patient's biology provides the cellular response.

It is important to be clear about terminology. ChondroFiller is the device — the collagen material itself. The ChondroFiller injection is the non-surgical delivery pathway: an ultrasound-guided outpatient procedure with no incision and no general anaesthetic. A separate surgical pathway, the Liquid Cartilage protocol (Professor Paul Y. F. Lee's keyhole technique combining the ChondroFiller scaffold with biological adjuncts and, where indicated, mesenchymal stem cells), exists for larger or more complex defects where a theatre-based approach is warranted. The two are distinct; this article focuses on the non-surgical injection.

How Does the ChondroFiller Injection Work?

The ChondroFiller injection is given under ultrasound guidance as a single, minimally invasive outpatient procedure. A fine needle is used to place the liquid collagen directly at the site of cartilage wear. Once inside, the material self-gels and adheres to the surrounding tissue without the need for sutures or additional fixatives.

The gel can absorb load and adapt to the mechanical forces present inside the joint (Weizel, A., Distler, T., Schneidereit, D., and Friedrich, O., 2020. Complex mechanical behavior of human articular cartilage and hydrogels for cartilage repair. Acta Biomaterialia). Over months, the scaffold is gradually resorbed and replaced by patient-derived repair tissue.

Published clinical evidence reports meaningful improvement in patient-reported outcomes, including approximately 30 points of improvement in IKDC scores in the knee over 12 to 36 months of follow-up. Results vary between patients. ChondroFiller is best understood as a supportive, joint-preserving injection with biological potential — not a guaranteed repair or reversal of arthritis.

What Can Patients Expect?

Assessment comes first. Not every patient with knee pain is a suitable candidate, and a thorough clinical evaluation — including imaging to characterise the defect — is necessary before proceeding. Suitability depends on defect size, location, and severity, as well as the patient's overall joint status.

The injection itself usually takes less than an hour and is performed as an outpatient procedure. Because no incision is made and no general anaesthetic is required, recovery is comparatively straightforward, and most patients can return to normal daily activities promptly. Some temporary soreness or swelling around the injection site is possible in the days following the procedure.

Early clinical experience is encouraging. The device has demonstrated a strong safety profile across a large number of uses since 2013. However, clinical evidence continues to develop, and individual outcomes cannot be guaranteed.

Who May Be Suited to the ChondroFiller Injection?

The ChondroFiller injection tends to be considered for patients with osteoarthritis or focal cartilage wear who want a non-surgical option and have not achieved adequate relief from conservative measures. It is generally better suited to moderate rather than very advanced arthritis, and to joints where the defect is accessible via ultrasound-guided injection.

People with very advanced joint destruction, active infection, inflammatory arthropathy, or certain other medical conditions may not be appropriate candidates. Patients for whom a larger or more complex cartilage defect is identified at assessment may be better served by the Liquid Cartilage surgical protocol, which allows direct visualisation and biological augmentation under arthroscopic conditions.

Thorough assessment by a specialist with experience in joint preservation is the starting point for any decision.

Important Considerations

ChondroFiller is a biologically active scaffold with a supportive and joint-preserving role. It is not a cure for arthritis and does not reverse established joint degeneration. The distinction between symptom management, biological support for cartilage repair, and structural joint reconstruction matters when discussing options with patients.

Published case series also note positive outcomes for the trapeziometacarpal joint in the hand (Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., and Lavagnolo, U., 2023. The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage). While this article focuses on the knee, it illustrates that the ChondroFiller injection has been evaluated across multiple joint types.

Conclusion

For patients with knee osteoarthritis or focal cartilage wear who are looking for a non-surgical, biologically active option, the ChondroFiller injection offers a single-step, outpatient approach with a favourable safety record. It is not appropriate for everyone, and the evidence, while promising, continues to mature.

At the London Cartilage Clinic, specialist assessment is available to determine whether the ChondroFiller injection, the Liquid Cartilage surgical protocol, or another pathway is most appropriate for your knee. A consultation provides clarity before any decision is made.